Table I.
Clinicopathological characteristics of the patients with NSCLC included in the present study.
| Characteristics | Number |
|---|---|
| Median age (n=454), (range) | 66 (35–91) |
| Sex (%) (n=454) | |
| Female, n | 172 (37.9) |
| Male, n | 282 (62.1) |
| Smoking history (%) (n=145) | |
| Yes, n | 132 (91.0) |
| No, n | 13 (9.0) |
| Histology (%) (n=432) | |
| SCC, n | 112 (25.9) |
| ADC, n | 290 (67.1) |
| NSCLC NOS, n | 24 (5.6) |
| Othera, n | 6 (1.4) |
| Sampling type (%) (n=416) | |
| Cytology, n | 87 (20.9) |
| Biopsy, n | 235 (56.5) |
| Surgical specimen, n | 94 (22.6) |
| Sample location (%) (n=414) | |
| Primary tumor | 260 (62.8) |
| LN | 88 (21.3) |
| Distant metastasis | 66 (15.9) |
| pT (%) (n=74) | |
| T1 | 43 (58.1) |
| T2 | 12 (16.2) |
| T3 | 14 (18.9) |
| T4 | 5 (6.8) |
| pN (%) (n=153) | |
| N0 | 50 (32.7) |
| N1–2 | 103 (67.3) |
| pM (%) (n=112) | |
| M0 | 42 (37.5) |
| M1 | 70 (62.5) |
| Stage (%) (n=112) | |
| 1 | 19 (17.0) |
| 2 | 16 (14.3) |
| 3 | 7 (6.2) |
| 4 | 70 (62.5) |
| FFPE block age (%) (n=453) | |
| <3 years | 446 (98.5) |
| ≥3 years | 7 (1.5) |
| EGFR mutation (%) (n=294) | |
| Yes | 26 (8.8) |
| No | 268 (91.2) |
| KRAS mutation (%) (n=289) | |
| Yes | 108 (37.4) |
| No | 181 (62.6) |
| TP53 mutation (%) (n=287) | |
| Yes | 108 (37.6) |
| No | 179 (62.4) |
| Other mutations (%) (n=289) | |
| Yes | 54 (18.7) |
| No | 235 (81.3) |
| Total number of mutations (%) (n=287) | |
| 0 | 61 (21.3) |
| 1 | 162 (56.4) |
| 2 | 53 (18.5) |
| 3 | 10 (3.5) |
| 4 | 1 (0.3) |
a
Other histology includes large cells carcinomas, sarcomatoid carcinomas, and pleomorphic carcinomas. pT, pN, pM and stage were revised according to the 8th UICC edition (26). ADC, adenocarcinoma; p, pathological; EGFR, epidermal growth factor receptor; FFPE, formalin-fixed paraffin-embedded; KRAS, KRAS proto-oncogene, GTPase; LN, lymph node metastasis; NOS, non-otherwise specified; SCC, squamous cell carcinoma; TP53, tumor protein p53.